Multiple Myeloma of Bone
2 clinical trials · Condition
◉ Watch Multiple Myeloma of Bone
| Record | Firm | Date |
|---|---|---|
| Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) (NCT04184050) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-04-13 |
Track Multiple Myeloma of Bone automatically
Every clearance here is in the API, with alerts when new ones post.